Treatment for Low Bone Mass with Significant Fracture Risk
Assessment of Fracture Risk
- The National Osteoporosis Foundation guidelines recommend treatment when the 10-year probability of hip fracture is ≥3% or the 10-year probability of major osteoporosis-related fracture is ≥20% based on FRAX 1
- A patient with a 10-year hip fracture risk of 3.8% exceeds the treatment threshold for hip fracture risk, according to the American College of Radiology 1, 3
- The American College of Radiology and the Journal of Clinical Oncology suggest that a patient's femoral neck T-score indicating low bone mass (osteopenia), combined with an elevated FRAX score, meets criteria for pharmacologic intervention 1, 2
First-Line Treatment Recommendations
- The American College of Internal Medicine recommends oral bisphosphonates (alendronate or risedronate) as first-line therapy for patients with low bone mass and significant fracture risk 3
- The American College of Clinical Oncology and the American College of Internal Medicine suggest that all treatment should include calcium (1200 mg/day) and vitamin D3 (800-1000 IU/day) supplementation 2, 3
Monitoring Recommendations
- The American College of Radiology recommends a follow-up DEXA scan after 2 years of therapy to assess treatment effectiveness 5
- The American College of Internal Medicine suggests that more frequent monitoring (annually) is not recommended during the pharmacologic treatment period 3
Lifestyle Modifications
- The Haematologica journal recommends weight-bearing exercise to improve bone density, as well as smoking cessation and limiting alcohol consumption for bone health 6
- The Praxis Medical Insights guidelines suggest implementing fall prevention strategies 4
Important Caveats
- The American College of Internal Medicine states that raloxifene and menopausal estrogen therapy are not recommended for osteoporosis treatment in this age group 3